Please refer to Phase I studies for more clinical trial opportunities

**Melanoma**

**Observational**
- IRB# 17104
  - DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study

**Uveal Melanoma**
- IRB# 21536
  - A Phase 2 trial of AU-011 via suprachoroidal administration designed to evaluate the safety and efficacy of AU-011 in subjects with primary indeterminate lesions and small choroidal melanoma
- IRB# 15661
  - A Phase III Randomized Trial Comparing Either High Dose Interferon or Ipilimumab to Pembrolizumab in Patients with High Risk Resected Melanoma

**Stage 2b or 2c**
- IRB# 19679
  - Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study

**Stage 2b, 2c or 3**
- IRB# 11848
  - Phase III Placebo-controlled trial of POL-103A Vaccine in Post-resection Melanoma Patients with High Risk of Recurrence

**Stage 3 or 4 Resectable**
- IRB# 11883
  - A Phase III, Randomized Study of Nivolumab with Ipilimumab vs. Ipilimumab or Nivolumab Monotherapy Post-resection
- IRB# 21882
  - A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

**Modern**
- A Phase II randomized study of adjuvant immunotherapy with Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

**CROSS-DISEASE TRIALS:**
- IRB# TBD
  - EAY131 (MATCH)
- IRB# TBD
  - S1609 (DART)

11/18/2020

http://www.ohsu.edu/research/rda/so/knight.php
Please refer to Phase I studies for more clinical trial opportunities

Melanoma
Stage 3 or 4, Unresectable

Mutation Specific

IRB# 19667
A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib+ Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients with BRAFV600-Mutant Melanoma Brain Metastasis

IRB# 16198
A phase 1, Dose Escalation Trial of Tumor Injections of TTI-621 in Subjects with Relapsed and Resistant Solid Tumors and Mycosis Fungoides

IRB# 18687
A Phase 3, Randomized, Open-label Study of NKTR-214 combined with nivolumab versus nivolumab in participants with previously untreated unresectable or metastatic melanoma.

Non-Mutation Specific

IRB# 19207
A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma (LEAP-003)

IRB# 19943
A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination with Pembrolizumab versus Pembrolizumab in Patients with Previously Untreated Advanced Melanoma

IRB# 19285
A Phase Ib/II Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma

IRB# 19667
A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib+ Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients with BRAFV600-Mutant Melanoma Brain Metastasis

http://www.ohsu.edu/research/rda/so/knight.php
Melanoma + Non-melanoma skin cancer

IRB 22389: A Phase 1b/2 Study of Cavrotolimod Combined with Pembrolizumab or Cemiplimab in Patients with Advanced Solid Tumors

http://www.ohsu.edu/research/rda/so/knight.php